Data Characteristics
Pharmacoeconomics quality documents include clinical trial reports, drug marketing application materials, Health Technology Assessment (HTA) reports, and drug use guidelines. These documents are typically in PDF, Word, or Excel formats. They cover drug efficacy, safety, cost, cost-effectiveness analysis, and budget impact analysis. Data sources are diverse, including clinical research data, real-world data, government data, and third-party databases. Updates are relatively stable, usually quarterly or annually, coinciding with drug lifecycle milestones (e.g., launch, indication expansion, price adjustment) or national policy changes. Document structures are complex, containing specialized terminology, charts, and statistical data, with cross-references between reports. Key fields include drug name, indication, treatment plan, treatment effect indicators (e.g., QALY, LYG), cost components (e.g., drug procurement cost, diagnostic fees, hospitalization fees), unit cost, discount rate, and sensitivity analysis parameters.
Constraints on Multi-Turn Conversations and Prompts
The complexity and specialized nature of pharmacoeconomics documents demand robust context management and prompt design for multi-turn conversations. Frequent abbreviations and specialized terms require strong entity recognition and disambiguation capabilities to ensure accurate conversation understanding. Extensive numerical data and units (e.g., USD/QALY, year, %) require the model to correctly identify and process them during extraction and calculation, preventing errors from unit confusion. Given the relatively fixed update frequency, the knowledge base needs regular maintenance and incremental updates to ensure timely conversation content. Cross-references between documents necessitate the multi-turn conversation system to integrate information across documents. For example, discussing a drug's cost-effectiveness may require referencing both its clinical trial data and HTA report. This requires prompt design to guide the model in logical reasoning and summarization from multiple sources to support in-depth discussions of complex issues.
Configuration Settings
| Configuration Item | Suggested Value | Rationale |
|---|---|---|
maxContext | 10 | Pharmacoeconomics conversations often involve complex reasoning, requiring longer historical context to prevent loss of core information. |
Chunk size (Chunk Length) | 800–1200 characters | Ensures each chunk contains a complete logical unit or key data point, such as a cost-effectiveness analysis paragraph. |
Recall count (Recall Count) | Top 8 | Increases the probability of recalling relevant information fragments from a large volume of specialized documents, covering more potential related data. |
Similarity threshold (Similarity Threshold) | 0.78 | Pharmacoeconomics terminology is highly specific; this threshold helps filter out low-relevance document segments, improving accuracy. |
Rerank result count (Reranked Return Count) | Top 5 | Further improves the ranking of the most relevant information after initial recall, optimizing model input quality. |
Model Temperature | 0.3 | Pharmacoeconomics Q&A requires rigor and objectivity; a lower temperature makes the model output more focused on knowledge base content and less divergent. |
Common Pitfalls
- The model fails to recognize or misinterprets key entities like drug names or treatment plans during a conversation, leading to off-topic or logically incorrect answers. This occurs when knowledge base chunking granularity is too large or too small, failing to capture entity context effectively, and prompts do not sufficiently guide the model for entity recognition.
- When a user asks about the cost-effectiveness of a specific drug, the model only provides partial cost data and cannot offer a complete efficacy evaluation. This happens when efficacy evaluation documents in the knowledge base are not correctly indexed, or prompts fail to effectively trigger multi-document associative retrieval.
- In multi-turn conversations, the model fails to remember specific drug parameters or calculation results discussed in previous turns, leading to repeated questions or logical breaks. This is due to a
maxContextparameter set too low, limiting the model's memory capacity for historical conversation information.
Verification of Configuration
- Test the model with typical pharmacoeconomics questions (e.g., "What is the ICER of drug X?") in multi-turn conversations to see if it accurately extracts and presents key numerical values and units, and can follow up based on previous information.
- Simulate in-depth user queries about a specific drug's cost composition and efficacy data. Check if the model can integrate information from different knowledge documents and provide coherent, logically consistent answers.
- Input questions containing specialized terminology and abbreviations. Observe if the model correctly understands and provides relevant explanations or data. This can be verified by checking if the model's output includes term definitions from the knowledge base.
- Test pharmacoeconomics scenarios of varying complexity. Evaluate the model's ability to perform multi-turn reasoning and information extraction while maintaining contextual consistency, ensuring conversational fluency and effectiveness.
The values provided are common starting points and should be measured against the reader's own samples.
Question material comes from public community discussions. Configuration values are common starting points and should be measured against your own samples. Verified on 2026-09-21.